Day One Biopharmaceuticals
Biotechnology ResearchCalifornia, United States201-500 Employees
Day One Biopharmaceuticals is a biotechnology research company focused on developing cancer therapies, with a particular emphasis on pediatric cancer. It operates as part of the Servier Group and collaborates with clinicians, families, and scientists to identify, acquire, and advance targeted cancer treatments. Its portfolio includes tovorafenib (OJEMDA), DAY301, and Emi-Le (emiltatug ledadotin), an antibody-drug conjugate in development for a rare cancer. The company is headquartered in Brisbane, California, and is positioned as a mid-sized biotechnology firm. In 2024, Day One formed a collaboration with the Children's Brain Tumor Network to advance pediatric oncology initiatives. The organization describes its approach as rethinking cancer drug development starting from Day One, with a focus on therapies applicable across ages.